MX2013006234A - Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero. - Google Patents
Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero.Info
- Publication number
- MX2013006234A MX2013006234A MX2013006234A MX2013006234A MX2013006234A MX 2013006234 A MX2013006234 A MX 2013006234A MX 2013006234 A MX2013006234 A MX 2013006234A MX 2013006234 A MX2013006234 A MX 2013006234A MX 2013006234 A MX2013006234 A MX 2013006234A
- Authority
- MX
- Mexico
- Prior art keywords
- life
- production
- circulatory half
- recombinant glycoproteins
- mammalian cells
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title abstract 4
- 108090000288 Glycoproteins Proteins 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 210000004962 mammalian cell Anatomy 0.000 title 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 abstract 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000002581 neurotoxin Substances 0.000 abstract 1
- 231100000618 neurotoxin Toxicity 0.000 abstract 1
- 231100000572 poisoning Toxicity 0.000 abstract 1
- 230000000607 poisoning effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01214—Glycoprotein 3-alpha-L-fucosyltransferase (2.4.1.214)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
- C12Y204/99001—Beta-galactoside alpha-2,6-sialyltransferase (2.4.99.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01008—Cholinesterase (3.1.1.8), i.e. butyrylcholine-esterase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se proporcionan en la presente métodos y sistemas de expresión recombinante para la producción de glicoproteínas recombinantes que tienen un contenido de ácido siálico aumentado y contienen predominantemente enlaces de ácido alfa 2-6 siálico. También se proporcionan en la presente glicoproteínas recombinantes que tienen una semivida en circulación in vivo aumentada. Una aplicación potencial de las glicoproteínas descritas en la presente es para el tratamiento y profilaxis de la intoxicación por neurotoxinas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161430256P | 2011-01-06 | 2011-01-06 | |
PCT/US2012/020535 WO2012094627A2 (en) | 2011-01-06 | 2012-01-06 | Method of production of recombinant glycoproteins with increased circulatory half-life in mammalian cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013006234A true MX2013006234A (es) | 2013-08-01 |
Family
ID=46457991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013006234A MX2013006234A (es) | 2011-01-06 | 2012-01-06 | Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero. |
Country Status (10)
Country | Link |
---|---|
US (2) | US20130243744A1 (es) |
EP (1) | EP2661492B1 (es) |
CN (2) | CN107267459A (es) |
AU (1) | AU2012204241A1 (es) |
BR (1) | BR112013016447A2 (es) |
CA (1) | CA2817765A1 (es) |
DK (1) | DK2661492T3 (es) |
MX (1) | MX2013006234A (es) |
SG (1) | SG190260A1 (es) |
WO (1) | WO2012094627A2 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
ES2733248T3 (es) | 2012-01-11 | 2019-11-28 | Sigma Aldrich Co Llc | Producción de proteínas recombinantes con glicoformas simples |
KR20220013460A (ko) * | 2014-03-04 | 2022-02-04 | 시그마-알드리치 컴퍼니., 엘엘씨 | 바이러스 내성 세포 및 이의 용도 |
WO2015142679A1 (en) * | 2014-03-16 | 2015-09-24 | Yvonne Rosenberg | Production of highly thermally stable recombinant cholinesterases for the detection, detoxification and decontamination of organophosphorus compounds |
US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
US20170306046A1 (en) | 2014-11-12 | 2017-10-26 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
MD3227325T2 (ro) * | 2014-12-01 | 2024-09-30 | Ferring Bv | Compoziții de inhibitor selectiv trans-semnalizare de IL-6 |
DK3226888T3 (da) | 2014-12-01 | 2021-07-12 | Ferring Bv | Administration af en selektiv inhibitor af il-6-trans-signalering |
EP3230438B1 (en) * | 2014-12-12 | 2024-12-04 | University of Copenhagen | N-glycosylation |
EP3042952A1 (en) * | 2015-01-07 | 2016-07-13 | CEVEC Pharmaceuticals GmbH | O-glycan sialylated recombinant glycoproteins and cell lines for producing the same |
IL302822A (en) * | 2015-11-12 | 2023-07-01 | Seagen Inc | Glycan-interacting compounds and methods of use |
JP2019530672A (ja) * | 2016-09-13 | 2019-10-24 | バイエル・ヘルスケア・エルエルシーBayer HealthCareLLC | 第viia因子グリコフォーム |
US11401330B2 (en) | 2016-11-17 | 2022-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
BR112019018043A2 (pt) | 2017-03-03 | 2020-04-07 | Seattle Genetics Inc | método de tratamento de câncer, e, conjugado de anticorpo-fármaco |
EP3570871B1 (en) | 2017-03-20 | 2020-11-18 | H. Hoffnabb-La Roche Ag | Method for in vitro glycoengineering of an erythropoiesis stimulating protein |
WO2019084310A1 (en) | 2017-10-25 | 2019-05-02 | Yoshihiro Kawaoka | HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION |
CN108659095A (zh) * | 2018-05-18 | 2018-10-16 | 上海药明生物技术有限公司 | 一种使唾液酸含量稳定的方法 |
WO2020033527A2 (en) | 2018-08-07 | 2020-02-13 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
EP3840780A1 (en) | 2018-08-20 | 2021-06-30 | Wisconsin Alumni Research Foundation | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein |
EP3921413A1 (en) * | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Humanized cell line |
WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
CN117587020B (zh) * | 2024-01-18 | 2024-04-02 | 中国人民解放军东部战区总医院 | 抑制ST3GAL1基因表达的shRNA及其应用 |
CN118755805A (zh) * | 2024-09-06 | 2024-10-11 | 天津舍为斯生物技术有限公司 | 一种唾液酸化酶qPCR芯片及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204431B1 (en) * | 1994-03-09 | 2001-03-20 | Abbott Laboratories | Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk |
US20020045207A1 (en) * | 1997-10-31 | 2002-04-18 | Lynne A. Krummen | Glycoprotein production process |
MXPA04003333A (es) * | 2001-10-10 | 2006-02-22 | Neose Technologies Inc | Remodelado y glicoconjugacion de peptidos. |
AU2002365933A1 (en) | 2001-11-14 | 2003-09-02 | Joseph D. Mosca | Production of recombinant therapeutic bioscavengers against chemical and biological agents |
EP1465987B1 (en) * | 2001-12-07 | 2008-01-23 | Crucell Holland B.V. | Production of viruses, viral isolates and vaccines |
US20070111279A1 (en) * | 2002-11-13 | 2007-05-17 | Procell, Inc. | Production of recombinant therapeutic bioscavengers against chemical and biological agents |
EP2115151B1 (en) * | 2006-12-28 | 2014-05-07 | Janssen Biotech, Inc. | Methods and vectors for generating asialylated immunoglobulins |
DK2195444T3 (en) * | 2007-10-12 | 2015-08-24 | Sigma Aldrich Co Llc | Cell line and methods for enhanced sialylation of glycoprotein. |
EP2389586B2 (en) * | 2009-01-22 | 2018-01-24 | Momenta Pharmaceuticals, Inc. | Galactose-alpha-1,3-galactose-containing n-glycans in glycoprotein products derived from cho cells |
-
2012
- 2012-01-06 DK DK12731900.2T patent/DK2661492T3/en active
- 2012-01-06 MX MX2013006234A patent/MX2013006234A/es unknown
- 2012-01-06 AU AU2012204241A patent/AU2012204241A1/en not_active Abandoned
- 2012-01-06 US US13/885,378 patent/US20130243744A1/en not_active Abandoned
- 2012-01-06 CN CN201710235794.3A patent/CN107267459A/zh active Pending
- 2012-01-06 CA CA2817765A patent/CA2817765A1/en not_active Abandoned
- 2012-01-06 SG SG2013036694A patent/SG190260A1/en unknown
- 2012-01-06 BR BR112013016447A patent/BR112013016447A2/pt not_active IP Right Cessation
- 2012-01-06 EP EP12731900.2A patent/EP2661492B1/en not_active Revoked
- 2012-01-06 CN CN2012800038173A patent/CN103221537A/zh active Pending
- 2012-01-06 WO PCT/US2012/020535 patent/WO2012094627A2/en active Application Filing
-
2016
- 2016-11-23 US US15/360,768 patent/US20170159095A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2012094627A3 (en) | 2012-10-04 |
EP2661492A2 (en) | 2013-11-13 |
BR112013016447A2 (pt) | 2019-09-24 |
WO2012094627A2 (en) | 2012-07-12 |
CN107267459A (zh) | 2017-10-20 |
DK2661492T3 (en) | 2018-01-15 |
EP2661492B1 (en) | 2017-10-04 |
SG190260A1 (en) | 2013-06-28 |
CN103221537A (zh) | 2013-07-24 |
US20130243744A1 (en) | 2013-09-19 |
US20170159095A1 (en) | 2017-06-08 |
AU2012204241A1 (en) | 2013-06-06 |
EP2661492A4 (en) | 2015-04-15 |
CA2817765A1 (en) | 2012-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013006234A (es) | Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero. | |
AR124871A2 (es) | Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes | |
MX366155B (es) | Celulas para producir iduronato-2-sulfatasa recombinante. | |
MX2013005654A (es) | Composiciones y metodos para la produccion de acido 3-hidroxipropionico. | |
AR078544A1 (es) | Procedimiento de cultivo de celulas de mamiferos para la produccion de proteinas | |
ECSP13012978A (es) | Inhibidores de glucosilceramida sintasa | |
BR112015019997A2 (pt) | Métodos de sacarificar e fermentar um material celulósico | |
MX339769B (es) | Sistemas, metodos y composiciones para optimizar injertos enriquecidos con celulas y tejidos. | |
MX2015007361A (es) | Produccion mediada por la proteina portadora de acilo de los derivados de acidos grasos. | |
MX349992B (es) | Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe. | |
PE20171799A1 (es) | Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada | |
TN2013000427A1 (en) | Modified acid alpha glucosidase with accelerated processing | |
BR112013017884A2 (pt) | varredura de microcolônia encapsulada com gel | |
MX366106B (es) | Composiciones y metodos para producir glucoproteinas. | |
WO2013136189A3 (en) | Methods and materials for treatment of pompe's disease | |
IN2015DN00976A (es) | ||
MY170889A (en) | Car enzymes and improved production of fatty alcohols | |
MX2016005824A (es) | Metodo de cultivo celular. | |
BR112014014151A2 (pt) | células fúngicas e processos de fermentação | |
MX2015004516A (es) | Procedimientos y sistemas para optimizar el sistema de cultivo de celulas de perfusion. | |
PH12014502870A1 (en) | Method of producing recombinant iduronate-2-sulfatase | |
MX2022002057A (es) | Variantes de enzima con propiedades de ester sintasa mejoradas. | |
WO2012115903A3 (en) | Yeast strain for the production of proteins with modified o-glycosylation | |
WO2011086447A3 (en) | Fermentation process for the preparation of recombinant heterologous proteins | |
MX2015010887A (es) | Formulaciones y metodos para aumentar la produccion de proteinas recombinantes. |